Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109195 · ClinicalTrials.gov registry record
A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant
A clinical trial, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- 7
- Enrollment target
NCT05109195: Clinical Trial study, sponsored by Janssen Research & Development.
NCT05109195 is a clinical trial that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05109195 was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety (adverse events, serious adverse events, deaths, suicidality) of participants with major depressive disorder (MDD) treated according to the standard of care (SOC).
Primary Outcome
Number of participants with spontaneously reported AEs will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Interventions
- OTHER Standard of Care (SOC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2022-10-19 |
Why NCT05109195 stopped before completion
NCT05109195 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Standard of Care (SOC) is the first listed.
NCT05109195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05109195 about?
NCT05109195 is a clinical study titled "A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant". The purpose of this study is to assess the safety (adverse events, serious adverse events, deaths, suicidality) of participants with major depressive disorder (MDD) treated according to the standard of care (SOC).
What is the current status of trial NCT05109195?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2021-10-26. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT05109195?
The interventions under investigation include: Standard of Care (SOC) (OTHER).
Who is sponsoring clinical trial NCT05109195?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI